The ABPI and the government have extended the deadline for companies to announce their exit from the 2024 voluntary scheme for branded medicine pricing, access, and growth (VPAG) to December 16, 2025.

This extension aims to provide companies with additional time and clearer information amid ongoing global uncertainties in the life sciences sector.

Companies that announce their exit before the new deadline cannot change their minds, and those that don’t must stay in the scheme until 2026.

Companies granted third extension to VPAG 2026 decision deadline – now set for 16 December